Why Shares of Cassava Sciences Jumped This Week
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam.
Source: fool.com
Page 40 - Cassava Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cassava Sciences Today - Breaking & Trending Today
FY2023 EPS Estimates for Cassava Sciences, Inc. Raised by HC Wainwright (NASDAQ:SAVA)
Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) – Investment analysts at HC Wainwright increased their FY2023 EPS estimates for shares of Cassava Sciences in a report issued on Tuesday, May 9th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn $0.84 per share for the year, up from their previous forecast of […]
Source: modernreaders.com
Adaptimmune Therapeutics (ADAP) Gets a Hold from JonesTrading
In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report). Th...
Source: businessinsider.com
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer's Disease
The Cognition Maintenance Study is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition... | May 11, 2023
Source: marketscreener.com
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer's Disease Seite 1
11.05.2023 - The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease.Primary Outcome Measures Are Safety and Change in Cognition Scores.Top-line Clinical Results of the CMS Are ... Seite 1
Source: wallstreet-online.de